Based on product, the dental bone graft substitute and barrier membranemarket is bifurcated into dental bone graft substitutes and dental barrier membranes. The dental bone graft substitutes segment held a larger market share in 2022; however, the dental barrier membranes segment is anticipated to register a higher CAGR of 9.1% during the forecast period.

Rising Burden of Periodontal Diseases and Oral Cancer Boosts Market Growth

Periodontal diseases range from simple gingivitis to serious conditions that cause significant damage to the soft tissues and bones supporting teeth; in a serious case, patients may lose their teeth. According to the World Health Organisation (WHO), as of 2023, ~3.5 billion people are affected with oral diseases across the world. Further, periodontal diseases affect 19% of the adult population, representing more than 1 billion cases globally. Poor oral hygiene and tobacco chewing are the main risk factors for periodontal disease. According to the article “The Link between Periodontal Disease and Oral Cancer—A Certainty or a Never-Ending Dilemma,” published by the Multidisciplinary Digital Publishing Institute (MDPI), more than 50% of the 18-year-old population in the US is likely to have periodontitis, and 75% of the population over 35 years is likely to be suffering from some form of periodontitis.

As per an article published in the National Library of Medicine (NLM) in 2020, the risk of developing chronic systemic conditions such as autoimmune diseases and cancer increases with periodontitis. Several risk factors linked to periodontitis and oral cancer include smoking, alcohol consumption, and the human papillomavirus. According to the World Cancer Research Fund International, with ~377,700 cases recorded globally in 2020, lips and the oral cavity are the most common sites of mouth and oral cancer. The US Department of Health and Human Services states oral cancer accounts for ~3% of cancer cases diagnosed annually in the US alone. Further, ~48,000 people are diagnosed with oral cancer, and ~9,600 die of the condition each year in the country. According to the CDC, mouth and throat cancer cases accounted for 3% of cancer cases diagnosed annually in the US in 2020. Periodontal disease plays an important role in the development of oral squamous cell carcinoma (OSCC). According to the Global Cancer Observatory (GCO), the annual incidence of OSCC in 2020 was 377,713 cases globally, with the highest number recorded in Asia (248,360), followed by Europe (65,279) and North America (27,469), and the five-year prevalence of OSCC approached ~1 million globally. Further, the incidence of OSCC is expected to increase by up to 40% by 2040.

A periodontal disease can lead to the resorption and failure of the alveolar bone, loss of periodontal attachment, and loosening and falling of the teeth. Therefore, the treatment of periodontal disease focuses on eliminating the source of infection, stimulating the synthesis of growth factors, and repairing periodontal tissue defects, ultimately restoring normal morphology and function. Correcting periodontal defects by bone grafting involves grafting materials (bone or bone substitutes) to restore the anatomical morphology of the alveolar bone and the function of the periodontal tissue. Therefore, the growing cases of periodontal diseases and oral cancer contribute to the growth of the dental bone graft substitute and barrier membrane market.

Dental Bone Graft Substitute and Barrier Membrane Market: Competitive Landscape and Key Developments

Geistlich Pharma AG, Medtronic Plc, Dentsply Sirona Inc, Matricel GmbH, ZimVie Inc, Regenity Biosciences Inc, Neoss UK & Ireland Ltd, Institut Straumann AG, CAMLOG Biotechnologies GmbH, and Resorba Medical GmbH are among the key companies operating in the dental bone graft substitute and barrier membranemarket. Leading players are adopting strategies such as the launch of new products, expansion and diversification of their market presence, and acquisition of new customer bases for tapping prevailing business opportunities.

• In April 2023, ZimVie announced the recent launch of RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug. The launch of these products has extended its portfolio of biomaterials intended for filling extraction sockets and periodontal defects. The products are commercially available in North America.
• in February 2020, Geistlich Pharma AG launched its unique product Geistlich Bio-Oss Collagen, which is a combination of Geistlich Bio-Oss and 10% porcine collagen. It is prescribed in various therapeutic areas, including ridge preservation, minor bone augmentation, and periodontal regeneration.
• In January 2021, Dentsply Sirona acquired Datum Dental, a leading provider of the innovative OSSIX regenerative solutions portfolio. With this acquisition, Dentsply Sirona could access a strong OSSIX biomaterial portfolio and the patented GLYMATRIX technology of Datum Dental, Ltd.
• In October 2022, Collagen Matrix acquired Polyganics, a medical technology company involved in the development and manufacturing of bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio of bioresorbable solutions and technology platforms for bone and tissue repair, unlocking new markets and clinical opportunities for the company.